- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06337448
Light Emitting Diode in the Treatment of Vulvodynia
March 22, 2024 updated by: Patricia Lordelo, Centro de Atenção ao Assoalho Pélvico
Light Emitting Diode in the Treatment of Vulvodynia: a Pilot Study
Vulvar pain can be related to a specific cause (inflammation, cancer, trauma, infection) or can be classified as vulvodynia, when vulvar pain is idiopathic and lasts for at least three months.
The main symptoms reported are pain, burning, erythema, increased sensitivity, itching and burning, which affect the quality of life, psycho-emotional well-being, relationships and sexual function of these women.
Photobiomodulation has been described in the literature as an alternative to treat pain.
Our group has studied blue LED for some vulvovaginal dysfunctions and, due to the positive sensory effects observed in patients with vaginal stenosis and genitourinary syndrome of menopause, it is hypothesized that this technique could also bring beneficial effects for women with vulvodynia.
A pilot study will be carried out, with descriptive data, with 10 women with vulvodynia.
Participants will be evaluated with a basic anamnestic questionnaire and sociodemographic data.
The following questionnaires will be used: Female Sexual Function Index (FSFI), Sexual Quotient - Female Version, Vulvar Pain Assessment Questionnaire.
After answering the questionnaires, the volunteer will undergo a perineal physical assessment by an experienced physiotherapist, which includes a) inspection of the genital region, reflex tests, assessment of the functions of the pelvic floor muscles, b) the cotton swab test to evaluate painful sensitivity in the vestibule, c) the tampon test to evaluate painful sensitivity in the introitus and vaginal canal.
Pain assessments will be quantified by the visual analogue pain scale (VAS), which ranges from 0 (no pain) to 10 (maximum pain).
At the end of the treatment, the participant will answer the questionnaires again, undergo reassessment of pain sensitivity in vulva, introitus and vaginal canal, of the function of the pelvic floor muscles and will be asked "What is your perception of improvement" and "What is your level of satisfaction with the treatment?".
The answers will be giving according to a Likert Scale of five points.
The LED application protocol will be carried out with external use equipment model Antares, from the company IBRAMED (Amparo, São Paulo, Brazil), with a cluster G2 applicator.
The power will be 450mW/cm2 and dose 5J/cm2 for 2 minutes and 13 seconds (automatic programming) in 450nm waves (blue wavelength).
The treatment consists of eight sessions, carried out daily, except on weekends.
Study Overview
Study Type
Interventional
Enrollment (Estimated)
10
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Patricia V Lordelo, Phd
- Phone Number: +5571996592400
- Email: pvslordelo@hotmail.com
Study Locations
-
-
Bahia
-
Salvador, Bahia, Brazil, 40290000
- Recruiting
- Centro de Atenção ao assoalho pélvico
-
Contact:
- Patricia Lordelo, post doc
- Phone Number: +5571988592400
- Email: pvslordelo@hotmail.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- vulvodynia diagnosis
Exclusion Criteria:
- patients diagnosed with vaginal infection
- difficulty in understanding the proposed instruments
- patients with chronic degenerative neurological diseases
- pregnant women
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Light-emitting diode
The LED application protocol will be carried out with external use equipment model Antares, from the company IBRAMED (Amparo, São Paulo, Brazil), with a cluster G2 applicator.
The power will be 450mW/cm2 and dose 5J/cm2 for 2 minutes and 13 seconds (automatic programming) in 450nm waves (blue wavelength).
The treatment consists of eight sessions, carried out daily, except on weekends.
The patient will remain naked, in a closed room, in the lithotomy position on a gynecological table, in the presence of only a physiotherapist specializing in women's health, who will apply the light.
|
The patient will remain naked, in a closed room, in the lithotomy position on a gynecological table, and he LED will be positioned in the direction of the patient's genitalia, keeping the internal and external vulvar lips open, so the LED can reach the largest possible region for therapeutic action.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with treatment-related adverse events as assessed by Visual Analogue Scale.
Time Frame: During the all 8 sessions (daily), at the end (one week after de beginning of the treatment) and one month after the end of the treatment.
|
To assess the safety of the treatment regarding the genital's sensation (burning, itching, pain) and genital's visual aspects (lesion, erosion, redness).
|
During the all 8 sessions (daily), at the end (one week after de beginning of the treatment) and one month after the end of the treatment.
|
Tolerability of participants to the treatment assessed by Likert Scale.
Time Frame: During the all 8 sessions (daily) and at the end (one week after de beginning of the treatment).
|
To assess the tolerability of the patient according to the Likert 5 Points Scale: very comfortable, comfortable, nor comfortable nor discomfortable, discomfortable, impossible to tolerate the treatment.
|
During the all 8 sessions (daily) and at the end (one week after de beginning of the treatment).
|
Evaluate the clinical response assessed by the Visual Analogue Scale.
Time Frame: At the beginning of the treatment and at the end (one week after de beginning of the treatment), 1, 3 and 6 months after the end treatment.
|
To assess the clinical effect of the treatment it will be used the Visual Analogue Scale (VAS), which varies from 0 to 10.
The pain will be assessed on the swab test and the tampon test in the genital area.
Minimum decrease in 2 points on the VAS will be interpretated as clinical effect.
|
At the beginning of the treatment and at the end (one week after de beginning of the treatment), 1, 3 and 6 months after the end treatment.
|
Evaluate the clinical response assessed by a questionnaire.
Time Frame: At the beginning of the treatment and at the end (one week after de beginning of the treatment), 1, 3 and 6 months after the end treatment.
|
To assess the clinical effect of the treatment it will be used the Vulvar Pain Assessment Questionnaire: the higher the score, the greater the intensity of pain and impairment of the assessed domains.
|
At the beginning of the treatment and at the end (one week after de beginning of the treatment), 1, 3 and 6 months after the end treatment.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate the sexual function of women with vulvodynia by Female Sexual Function Index (FSFI).
Time Frame: At the beginning of the treatment and at the end (one week after de beginning of the treatment), 1, 3 and 6 months after the end of the treatment.
|
The FSFI has 19 items, the score varies from 2 to 36, and the cut-off point is 26, meaning that scores of 26 or less classify the patient as having sexual dysfunction.
|
At the beginning of the treatment and at the end (one week after de beginning of the treatment), 1, 3 and 6 months after the end of the treatment.
|
Evaluate the sexual function of women with vulvodynia by Sexual Quotient - Female Version (SQ-FV).
Time Frame: At the beginning of the treatment and at the end (one week after de beginning of the treatment), 1, 3 and 6 months after the end treatment.
|
The FQ-SV has 10 items and the score varies from 0 to 100.
Higher values indicate better sexual performance/satisfaction.
The score classification is 82-100 points: good to excellent; 62-80 points: regular to good; 42-60 points: unfavorable to fair; 22-40 points: poor to unfavorable; 0-20 points: nil to bad.
A cutoff point of 60 (between 48 and 84) was established as a means of screening for female sexual dysfunction.
|
At the beginning of the treatment and at the end (one week after de beginning of the treatment), 1, 3 and 6 months after the end treatment.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 16, 2024
Primary Completion (Estimated)
January 1, 2026
Study Completion (Estimated)
December 1, 2026
Study Registration Dates
First Submitted
March 4, 2024
First Submitted That Met QC Criteria
March 22, 2024
First Posted (Actual)
March 29, 2024
Study Record Updates
Last Update Posted (Actual)
March 29, 2024
Last Update Submitted That Met QC Criteria
March 22, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 74090923.9.0000.5544
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vulvodynia
-
University Hospital, GhentCompletedLocalized Provoked VulvodyniaBelgium
-
Oregon Health and Science UniversityMedical Research Foundation, OregonCompleted
-
Meir Medical CenterCompleted
-
McLean Center for Complementary and Alternative...UnknownVulvodynia | Vulvar Vestibulitis | Vulvodynia, Generalized | Vulvar PainUnited States
-
Meir Medical CenterCompletedLocalized Provoked VulvodyniaIsrael
-
Uppsala UniversityCompletedVulvodynia, Generalized | Provoked VestibulodyniaSweden
-
Oregon College of Oriental MedicineOregon Health and Science University; National Vulvodynia Association; Council...CompletedVulvodynia | Vulvar Vestibulitis | Provoked Vestibulodynia | Provoked, Localized VulvodyniaUnited States
-
University of Illinois at ChicagoUniversity of FloridaCompletedVulvodynia | Vulvar Vestibulitis | Vulvodynia, GeneralizedUnited States
-
Colleen StockdaleTerminatedVulvar Pain Symptoms | Vulvodynia (Chronic Vulvar Pain)United States
-
University of TennesseeUniversity of Tennessee Health Science CenterCompleted
Clinical Trials on Blue LED
-
Erebouni Medical CenterRecruitingNeonatal Hyperbilirubinemia | Jaundice, NeonatalArmenia
-
Centro de Atenção ao Assoalho PélvicoUniversity of Messina; Vitale SG M.D.RecruitingCandidiasis, VulvovaginalBrazil
-
Toyos ClinicWithdrawnMeibomian Gland DysfunctionUnited States
-
Universidade Federal do ParaCompletedColor | Bleaching SensitivityBrazil
-
Centro de Atenção ao Assoalho PélvicoUniversity of Messina; Salvatore Giovanni Vitale M.D.RecruitingVaginosis, BacterialBrazil
-
University of BergenGlamoxCompletedSleep | Sleep Deprivation | Shift-Work Related Sleep DisturbanceNorway
-
GE HealthcareCompleted
-
Philips Electronics Nederland BVCompletedLow Back Pain | Musculoskeletal Pain | Chronic Pain | Low Back Pain, RecurrentGermany
-
Universidade Estadual de LondrinaCompleted
-
VA Office of Research and DevelopmentActive, not recruitingTraumatic Brain Injury | Posttraumatic Stress DisorderUnited States